GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » ROC (Joel Greenblatt) %

InterMune (FRA:IUX) ROC (Joel Greenblatt) % : -5,710.18% (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is InterMune ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. InterMune's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2014 was -5,710.18%.

The historical rank and industry rank for InterMune's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:IUX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8945.36   Med: -1467.59   Max: 5020.96
Current: -4593.93

During the past 13 years, InterMune's highest ROC (Joel Greenblatt) % was 5020.96%. The lowest was -8945.36%. And the median was -1467.59%.

FRA:IUX's ROC (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -333.95 vs FRA:IUX: -4593.93

InterMune's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


InterMune ROC (Joel Greenblatt) % Historical Data

The historical data trend for InterMune's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InterMune ROC (Joel Greenblatt) % Chart

InterMune Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,984.77 5,485.87 -8,967.88 -5,831.85 -4,449.47

InterMune Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,576.74 -4,250.56 -4,542.66 -4,238.42 -5,710.18

Competitive Comparison of InterMune's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, InterMune's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InterMune's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where InterMune's ROC (Joel Greenblatt) % falls into.



InterMune ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2014 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(18.538 + 8.063 + -26.601) - (43.016 + 0 + 0.129)
=-43.145

Working Capital(Q: Jun. 2014 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(22.83 + 8.09 + 8.267) - (51.044 + 0 + 0)
=-11.857

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of InterMune for the quarter that ended in Jun. 2014 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2014 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2014  Q: Jun. 2014
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-198.6/( ( (3.343 + max(-43.145, 0)) + (3.613 + max(-11.857, 0)) )/ 2 )
=-198.6/( ( 3.343 + 3.613 )/ 2 )
=-198.6/3.478
=-5,710.18 %

Note: The EBIT data used here is four times the quarterly (Jun. 2014) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InterMune  (FRA:IUX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


InterMune ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of InterMune's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


InterMune (FRA:IUX) Business Description

Traded in Other Exchanges
N/A
Address
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune (FRA:IUX) Headlines

No Headlines